Daniela Corna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10148877/publications.pdf

Version: 2024-02-01

57631 69108 6,333 78 44 77 citations h-index g-index papers 78 78 78 6135 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. Journal of the American Society of Nephrology: JASN, 2004, 15, 1794-1804.	3.0	690
2	Disruption of the Ang II type 1 receptor promotes longevity in mice. Journal of Clinical Investigation, 2009, 119, 524-530.	3.9	434
3	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	1.4	351
4	Insulin-Like Growth Factor-1 Sustains Stem Cell–Mediated Renal Repair. Journal of the American Society of Nephrology: JASN, 2007, 18, 2921-2928.	3.0	294
5	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney International, 1993, 44, 440-444.	2.6	215
6	Add-On Anti–TGF-β Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. Journal of the American Society of Nephrology: JASN, 2003, 14, 1816-1824.	3.0	177
7	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach. Journal of the American Society of Nephrology: JASN, 2002, 13, 2898-2908.	3.0	156
8	In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions. Journal of the American Society of Nephrology: JASN, 2012, 23, 1857-1868.	3.0	156
9	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney International, 1993, 43, 354-358.	2.6	153
10	Protein traffic activates NF-kB gene signaling and promotes MCP-1–dependent interstitial inflammation. American Journal of Kidney Diseases, 2000, 36, 1226-1241.	2.1	145
11	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney International, 1997, 52, 171-181.	2.6	138
12	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney International, 1997, 51, 1583-1589.	2.6	134
13	Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals. Journal of the American Society of Nephrology: JASN, 1999, 10, 1542-1549.	3.0	126
14	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nature Communications, 2017, 8, 983.	5.8	124
15	Protein Overload Induces Fractalkine Upregulation in Proximal Tubular Cells through Nuclear Factor κB– and p38 Mitogen-Activated Protein Kinase–Dependent Pathways. Journal of the American Society of Nephrology: JASN, 2003, 14, 2436-2446.	3.0	118
16	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. American Journal of Physiology - Renal Physiology, 2009, 297, F1448-F1456.	1.3	114
17	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight, 2018, 3, .	2.3	114
18	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia Journal of Clinical Investigation, 1990, 86, 1768-1771.	3.9	110

#	Article	IF	CITATIONS
19	Proximal tubular cells promote fibrogenesis by TGF-β1–mediated induction of peritubular myofibroblasts. Kidney International, 2002, 61, 2066-2077.	2.6	109
20	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney International, 2002, 61, 1635-1645.	2.6	103
21	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. American Journal of Kidney Diseases, 1996, 27, 416-423.	2.1	99
22	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 804-813.	3.0	99
23	Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. American Journal of Physiology - Renal Physiology, 2013, 304, F808-F819.	1.3	90
24	Proteasomal Processing of Albumin by Renal Dendritic Cells Generates Antigenic Peptides. Journal of the American Society of Nephrology: JASN, 2009, 20, 123-130.	3.0	88
25	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. American Journal of Physiology - Renal Physiology, 2012, 303, F1370-F1381.	1.3	88
26	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy1. Kidney International, 1998, 54, 353-359.	2.6	77
27	Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator–Activated Receptor-γ Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone. Journal of the American Society of Nephrology: JASN, 2006, 17, 1624-1632.	3.0	76
28	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. PLoS ONE, 2013, 8, e70775.	1.1	75
29	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. American Journal of Kidney Diseases, 1997, 29, 254-264.	2.1	74
30	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney International, 1998, 53, 726-734.	2.6	71
31	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney International, 2006, 70, 97-103.	2.6	71
32	<i>Sirt3</i> Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by <i>Opa1</i> Gene Transfer. Antioxidants and Redox Signaling, 2019, 31, 1255-1271.	2.5	70
33	Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 1158-1167.	3.0	63
34	β-Arrestin-1 Drives Endothelin-1–Mediated Podocyte Activation and Sustains Renal Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 523-533.	3.0	63
35	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin–angiotensin system inhibition in rats with renal mass reduction. Kidney International, 2009, 76, 960-967.	2.6	56
36	Distinct cardiac and renal effects of ET _A receptor antagonist and ACE inhibitor in experimental type 2 diabetes. American Journal of Physiology - Renal Physiology, 2011, 301, F1114-F1123.	1.3	56

#	Article	IF	CITATIONS
37	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. American Journal of Kidney Diseases, 1998, 31, 453-463.	2.1	55
38	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney International, 2004, 66, 1959-1965.	2.6	52
39	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology: JASN, 2014, 25, 1786-1798.	3.0	52
40	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. Journal of the American Society of Nephrology: JASN, 2016, 27, 1400-1411.	3.0	51
41	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. Scientific Reports, 2020, 10, 8418.	1.6	51
42	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International, 2001, 60, 653-663.	2.6	49
43	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. American Journal of Physiology - Renal Physiology, 2010, 299, F1203-F1211.	1.3	49
44	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis and Rheumatism, 2007, 56, 1629-1637.	6.7	46
45	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight, 2020, 5, .	2.3	46
46	Angiotensin-Converting Enzyme nhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist. American Journal of Pathology, 2001, 159, 1743-1750.	1.9	45
47	Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy. Nephron Experimental Nephrology, 1998, 6, 121-131.	2.4	44
48	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with $\hat{l}\pm 3$ chain of type IV collagen. Kidney International, 1998, 54, 1550-1561.	2.6	43
49	Beneficial Effect of TGFβ Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. Nephron Experimental Nephrology, 2006, 104, e158-e168.	2.4	43
50	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. Nephron, 2015, 129, 52-61.	0.9	43
51	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. American Journal of Kidney Diseases, 1999, 33, 746-753.	2.1	42
52	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. Nephron, 2016, 132, 59-69.	0.9	36
53	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. Journal of Immunology, 2012, 189, 3661-3668.	0.4	35
54	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. American Journal of Medicine, 1992, 92, S60-S63.	0.6	31

#	Article	IF	CITATIONS
55	Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria. Journal of the American Society of Nephrology: JASN, 2004, 15, 2666-2674.	3.0	31
56	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positiveÂadd-on effect in experimental diabeticÂnephropathy. Kidney International, 2019, 96, 906-917.	2.6	31
57	B7–1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 999-1005.	3.0	30
58	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Research and Therapy, 2018, 9, 220.	2.4	26
59	17β-Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. American Journal of Physiology - Renal Physiology, 2000, 279, F626-F635.	1.3	25
60	A previously unrecognized role of C3a in proteinuric progressive nephropathy. Scientific Reports, 2016, 6, 28445.	1.6	22
61	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. JCI Insight, 2019, 4, .	2.3	21
62	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the <scp>VEGFâ€A</scp> /caveolinâ€1/ <scp>PV</scp> â€1 signaling pathway. Journal of Pathology, 2022, 256, 468-479.	2.1	21
63	Sequence of Glomerular Changes in Experimental Endotoxemia: A Possible Model of Hemolytic Uremic Syndrome. Nephron, 1989, 53, 330-337.	0.9	19
64	Renal Primordia Activate Kidney Regenerative Events in a Rat Model of Progressive Renal Disease. PLoS ONE, 2015, 10, e0120235.	1,1	17
65	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney International, 2003, 64, 857-863.	2.6	13
66	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Therapy, 2009, 16, 1373-1379.	2.3	13
67	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. American Journal of Physiology - Renal Physiology, 2011, 300, F1291-F1300.	1.3	13
68	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. American Journal of Nephrology, 2007, 27, 630-638.	1.4	12
69	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. Scientific Reports, 2021, 11, 23580.	1.6	10
70	Simplified Method to Measure Glomerular Filtration Rate by Iohexol Plasma Clearance in Conscious Rats. Nephron, 2016, 133, 62-70.	0.9	9
71	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. Diabetes, 2018, 67, 2069-2083.	0.3	8
72	Oral zeranol shortens the prolonged bleeding time of uremic rats. Kidney International, 1990, 38, 96-100.	2.6	5

#	Article	IF	CITATIONS
73	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. Nephron, 2021, 145, 428-444.	0.9	5
74	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. Stem Cell Research, 2021, 55, 102476.	0.3	4
75	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. Cells, 2022, 11, 1755.	1.8	3
76	A Study of Low-Nutrient Diets Used for Aging Studies in the Rat. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1996, 51A, B270-B275.	1.7	2
77	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. Journal of Immunology, 2022, 208, 1772-1781.	0.4	2
78	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. Cell Transplantation, 2020, 29, 096368972096546.	1.2	1